Amol Kavishwar

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index508citations42works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(25), RNA modifications and cancer(14), RNA Interference and Gene Delivery(8), Advanced biosensing and bioanalysis techniques(7), Nanoparticle-Based Drug Delivery(6)

Publications42 total

Supplementary Fig. S3 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S6 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Data from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S2 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S1 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Video S8 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S6 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Video S8 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S4 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Data from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S5 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S7 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S2 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S1 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S7 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S3 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S4 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
supplemental figure legends from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
Supplementary Fig. S5 from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
supplemental figure legends from Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Zdravka Medarova(29), Byunghee Yoo(25), Alana Ross(24), Pamela Pantazopoulos(24), Victoria Petkova(22), Doris P. Tabassum(21), Kornélia Polyák(21), Natalia Barteneva(21), Aseda Tena(21), Anna Moore(20), Ping Wang(16), Anna Moore(9), José A. Halperin(3), Mehmet V. Yigit(2), Subrata Ghosh(2), Ping Wang(2), Ashok K. Chaturvedi(2), Anna Moore(2), Sonia Cantel(2), Allison B. Goldfine(2)